Exheus develops an RNA‑based diagnostic platform that analyzes expression of all genes in the blood transcriptome to detect health anomalies and produce personalized clinical recommendations. The company positions its test as the most advanced commercial RNA analysis technology in the world and has launched initial products to validate biomarkers and assess market fit. Exheus was founded in mid‑2020 as a spin‑off of Hospital Sant Pau – IIB Sant Pau and UPC and was incubated at The Collider (Mobile World Capital Barcelona). Future plans include international expansion into European health systems, building a commercial structure to access those systems, completing regulatory requirements for cross‑border operation, and digitizing the product into a B2B automated interactive platform for clinicians. On the financial side, Exheus has previously raised more than €500k in 2021 and continues to secure non‑dilutive and equity financing to fund growth.

Total raised

$53M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2022